Compare LYRA & PRPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LYRA | PRPH |
|---|---|---|
| Founded | 2005 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 4.1M |
| IPO Year | 2020 | 1997 |
| Metric | LYRA | PRPH |
|---|---|---|
| Price | $3.41 | $0.45 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $16.00 | N/A |
| AVG Volume (30 Days) | 35.1K | ★ 2.7M |
| Earning Date | 11-12-2025 | 11-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $600,000.00 | ★ $5,055,000.00 |
| Revenue This Year | N/A | $221.82 |
| Revenue Next Year | $93.90 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.84 | $0.50 |
| 52 Week High | $37.50 | $9.35 |
| Indicator | LYRA | PRPH |
|---|---|---|
| Relative Strength Index (RSI) | 35.73 | 56.08 |
| Support Level | $3.19 | $0.08 |
| Resistance Level | $3.70 | $1.15 |
| Average True Range (ATR) | 0.32 | 0.08 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 19.81 | 34.33 |
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
ProPhase Labs Inc is a diversified company offering various services, including diagnostic testing, genomics testing, and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers, and government organizations. The Consumer Products segment is engaged in the research, development, manufacture, distribution, marketing, and sale of OTC consumer healthcare products and dietary supplements in the United States. It also provides personal genomics products and services.